Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2495116 | 0.82 | MET (0.80) | METKDM4ESMN1; SMN2MEN1PKM | |
| SCHEMBL5557932 | 0.82 | MET (0.75) | METKDM4ESMN1; SMN2MEN1PKM | |
| SCHEMBL13888410 | 0.81 | MET (0.78) | METKDM4ESMN1; SMN2MEN1PKM | |
| SCHEMBL2499710 | 0.81 | MET (0.78) | METKDM4ESMN1; SMN2MEN1PKM | |
| SCHEMBL2266182 | 0.81 | MET (1.00) | METKDM4ESMN1; SMN2MEN1PKM | |
| SCHEMBL2496343 | 0.81 | MET (0.78) | METKDM4ESMN1; SMN2MEN1PKM | |
| SCHEMBL2492967 | 0.81 | MET (0.78) | METKDM4ESMN1; SMN2MEN1PKM | |
| SCHEMBL2495841 | 0.80 | MET (0.72) | METKDM4ESMN1; SMN2MEN1PKM | |
| SCHEMBL2498143 | 0.79 | MET (0.73) | METKDM4ESMN1; SMN2MEN1PKM | |
| SCHEMBL5519964 | 0.78 | MET (0.73) | METKDM4ESMN1; SMN2MEN1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966214-B9 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-1966214-B9 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-13 | — | — | EP | disclosed |
| EP-1966214-B1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-02 | — | — | EP | disclosed |
| EP-1966214-B1 | TRIAZOLOPYRIDAZINES AS TYROSINE KINASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-02 | — | — | EP | disclosed |
| US-8173654-B2 | Triazolopyridazine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-08 | — | — | US | disclosed |
| US-8173654-B2 | Triazolopyridazine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-08 | — | — | US | disclosed |
| US-8173654-B2 | Triazolopyridazine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-08 | — | — | US | disclosed |
| US-8030305-B2 | Triazolopyridazines as kinase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-04 | — | — | US | disclosed |
| US-8030305-B2 | Triazolopyridazines as kinase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-04 | — | — | US | disclosed |
| US-8030305-B2 | Triazolopyridazines as kinase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-10-04 | — | — | US | disclosed |
| US-20090098181-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098181-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| US-20090098181-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-16 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203136-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | RET, MET, ABL1 | MET 2/4885KDM4E 1028/4885SMN1; SMN2 3602/4885 |
| US-20090098181-A1 | TRIAZOLOPYRIDAZINES AS KINASE MODULATORS | RET, MET, ABL1 | MET 2/4885KDM4E 1028/4885SMN1; SMN2 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.